Mikhail Blagosklonny currently serves as the professor of Oncology at Rosewell Park Cancer Institute which is located in Buffalo, New York. Over the years Blagosklonny has been conducting researches on cancer and some of its therapies. Blagosklonny besides being an academician is also the Editor in Chief of Oncotarget journal and has published a lot of research on the topic of aging. Blagosklonny has contributed a lot in finding better treatment methods for cancer at a relatively lower cost that everyone could afford. One of Blagosklonny major achievements is in the research on the healing properties of Rapamycin. Rapamycin is a drug that plays a very critical role when it comes to organ transplant. The drug which is also known as Sirolimus helps prevent organ rejection during an organ transplant.
Rapamycin besides is used in coronary stents coating and also in the treatment of a rare lung disease known as Lymphangioleiomyomatosis (LAM). Of particular interest to Blagosklonny is Rapamycin ability to treating cancer.Rapamycin was first discovered in 1972 and was then used as an anti-fungal agent. On further testing, it was realized that the drug had some tremendous immunosuppressive and antiproliferative properties. These amazing properties of the drug made physicians abandon the use of the drug as an anti-fungal agent. Rapamycin has turned out to be one of the best drugs due to its immunosuppressant properties. These properties have made it possible for surgeons to carry out organ transplant without the fear of rejections. Prior to the discovery of Rapamycin in cases of organ rejection doctors used to prescribe anti-rejection drugs or calcineurin inhibitors. However, these drugs had some adverse effects on the kidney once used over a long period of time. This is where Rapamycin comes into play as the drug when used as an immunosuppressive drug during transplant has little to no effect towards the kidney.
Rapamycin due to its incredible healing properties is used in the treatment of diseases such as hemolytic-uremic syndrome, Lymphangioleiomyomatosis (LAM), coronary stent coating, Tuberous Sclerosis Complex (TSC), Facial angiofibromas and cancer.Mikhail Blagosklonny besides being a professor and an editor is also a philanthropist. Part of his philanthropic activities is in making sure that cancer patients around the world get the best type of treatment regardless of their social economic status. To achieve this goal Blagosklonny is conducting extensive research on cancer and aging and more specifically the relationship between the two as cancer tends to attack individuals who have reached a certain age. Blagosklonny has made a positive mark in the field of oncology and has been a source of inspiration to his peers and students who are aiming to advance research in oncology.Mikhail Blagosklonny published articles on different topics especially in regards to cancer and aging has earned him recognition in the medical field and on impactjournals.com. Mikhail Blagosklonny goal is not only in finding the cure for cancer disease but also finding a treatment method that is less painful and affordable as opposed to the current excruciating and expensive treatment method that only a few wealthy people can afford.